PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer

The purpose of this prostate cancer research study is to learn about: 1. Improving control of prostate cancer using radiation therapy, delivered to the para-aortic and pelvic lymph nodes, in addition to systemic androgen suppression therapy; 2. Preserving quality of life after radiation therapy; 3. Leveraging imaging results from prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) scans to evaluate and manage disease progression.

Trial Details

NCT ID
NCT06392295
Phase
PHASE2
Sponsor
University of Miami
Status
RECRUITING
Cancer Type
Hormone-Sensitive Prostate Cancer
Interventions
  • Para Aortic Radiation Therapy: Photon Therapy
  • Para Aortic Radiation Therapy: Proton Therapy
  • Androgen Deprivation Therapy
  • Androgen Receptor Signaling Inhibitor
Locations (sample)
  • Miami, Florida, United States|25.77427,-80.19366

Key Eligibility Criteria

  • Histologically proven prostate adenocarcinoma
  • Male, ≥ 18 years old
  • Oligorecurrent disease limited to the sub-diaphragmatic region with or without pelvic lymph nodes
  • a. No more than a total of 5 lesions on PSMA PET/CT scan (each lesion defined as positive with standardized uptake value (SUV) \> liver uptake and …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hormone-Sensitive Prostate Cancer Trials on Trialify →